<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="459">
  <stage>Registered</stage>
  <submitdate>8/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <actrnumber>ACTRN12605000407695</actrnumber>
  <trial_identification>
    <studytitle>ESPRIT TOXIL-2  UNSW PSO 6361</studytitle>
    <scientifictitle>An open-label, randomised study comparing the uptake of rIL-2 in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT: Toxicity substudy of ESPRIT: TOXIL-2 substudy</scientifictitle>
    <utrn />
    <trialacronym>ESPRIT TOXIL-2</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>rlL-2 toxicity
</healthcondition>
    <healthcondition>Interleukin-2 therapy</healthcondition>
    <healthcondition>HIV</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This substudy is an open-label, randomised study comparing the uptake of rIL-2 in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT. The design is a factorial one with 4 arms, all patients will receive regular ibuprofen and paracetamol from days 1-6 of the rIL-2 dosing cycle in addition, patients will be randomised to receive one of two antiemetic combinations i.e. ondansetron or metoclopramide with or without low dose codeine phosphate as an additional analgesic agent. The intervention will occur for 6 days beginning at day 1 of the rIL-2 dosing cycle and finishing one day after the last dose of rIL-2 on day 5.  It is protocol mandated that patients must receive a minimum of one dosing cycle of rIL-2 during the 6 months in which they are randomised into this substudy. However, if desired they can receive more than one dosing cycle of rIL-2 during this 6 mth period provided that they are not at the CD4+ T-cell goal for the study, it is medically safe for them to do so and that cycling does not occur more frequently than every 6-11 weeks (as per the ESPRIT protocol).</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of planned rIL-2 taken during the first rIL-2 dosing cycle while participating in this substudy.  The information will be transcribed onto a standardised CRF.</outcome>
      <timepoint>Assessed at day 1 (day 1 of the dosing cycle of rIL-2), day 5 and day 10 by means of adherence assessment and patient diaries.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean amount of rIL-2 taken during the cycle in million international units (MIU).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of cycles initiated</outcome>
      <timepoint>During the 6 month period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of planned rIL-2 taken during the cycles</outcome>
      <timepoint>After the first cycle.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean difference in rIL-2 taken during each cycle in the six-month period following randomisation into this substudy and rIL-2 uptake during the last dosing cycle immediately prior to participation in the substudy.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean time between receipt of rIL-2 on this substudy and the last dosing cycle of rIL-2 prior to entry into the substudy.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with dose modifications during the cycle due to toxicity.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients completing any cycle initiated.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with grade 1-4 GI toxicities.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with grade 1-4 constitutional upset (defined as any or all of the following: flu-like illness/fever/myalgia/arthalgia/headache).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with grade 1-4 oedema and/or other clinical manifestations of capillary leak syndrome eg pulmonary oedema.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with equal to or greater than 10% weight gain during rIL-2 dosing.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grade 1-4 creatinine changes during and after rIL-2 dosing.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grade 1-4 serum sodium changes during and after rIL-2 dosing.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in quality of life during and after rIL-2.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of use of breakthrough adjunctive therapies.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety of adjunctive agents as measured by grade 1-4 toxicity attributed to any of the adjunctive agents.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of serious adverse events (SAEs) (considered rIL-2-related or related to one of the adjunctive agents) and grade 4 clinical events during and within 8 weeks of the rIL-2 dosing cycle - CD4+ T-cell count change.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients indicating willingness to receive further rIL-2 following first rIL-2 cycle.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The study visits are screening; baseline (day 1 of the rIL-2 dosing cycle), day 5 of the rIL-2 dosing cycle, day 10 of the rIL-2 dosing cycle and day 60 of the rIL-2 dosing cycle. </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment on day 1 and day 60 include a brief clinical assessment and quality of life (QoL) survey over the past 4 weeks; QoL surveys over the past 24 hrs are conducted on day 5 and 10 of the rIL-2 dosing cycle. Blood draws for CD4+ T-cells.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients participating in ESPRIT and randomised to the rIL-2 arm, who: 1. are not at CD4+ T-cell target for the protocol;2. have not received rIL-2 for &gt;2 months;3. have reported both GI upset and constitutional side-effects as one of the reasons for either dose modifying in prior cycles or unwillingness to receive further rIL-2;4. are considered by the Investigator as medically safe to receive further dosing with rIL-2; 5. are willing to receive further dosing with rIL-2 at the dose specified by the Investigator; 6. are willing to sign informed consent to participate in the substudy.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. All exclusions for the receipt of rIL-2 on ESPRIT, 2. Known allergy to non-steroidal anti-inflammatory drugs (NSAIDS), opiates, 5HT-3 (serotonin-3) inhibitors, anti-dopaminergic antiemetics, or any other components of the proposed adjunct regimens.3. Use of other NSAIDS, cyclooxygenase-2 (COX-2) inhibitors, corticosteroids) or opiates analgesics within two weeks of rIL-2 dosing. Use of low dose aspirin as a cardio-protective agent is allowed.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealment will be addressed by use of a single computer allocation. Central randomisation will take place by phone/fax. Computer generated randomisation links will be provided by NCHECR. Links will be stratified by planned dose of recombinant interlukin-2 (IL-2), and will be blocked using a factor held at NCHECR.</concealment>
    <sequence>Sequence generation will be adjusted according to block size. The Coordinating Centre for the study (based at the National Centre in HIV Epidemiology and Clinical Research (NCHECR), UNSW) and all investigators will remain blinded to the actual block sizes used.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/09/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>168</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of New South Wales, Sydney, Australia.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of New South Wales</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Australian Department of Health and Ageing Therapeutic Goods Administration</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This substudy is an open-label, randomised study comparing the uptake of rIL-2 in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT. The design is a factorial one with 4 arms, all patients will receive regular ibuprofen and paracetamol from days 1-6 of the rIL-2 dosing cycle in addition, patients will be randomised to receive one of two antiemetic combinations i.e. ondansetron or metoclopramide with or without low dose codeine phosphate as an additional analgesic agent.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincents Hospital</ethicname>
      <ethicaddress>Sydney NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry> Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress> Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nambour Hospital</ethicname>
      <ethicaddress>Nambour, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>AIDS Medical Unit</ethicname>
      <ethicaddress>Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Carton Clinic</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Sexual health Clinic</ethicname>
      <ethicaddress>Miami, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cairns Base Hospital</ethicname>
      <ethicaddress>Cairns, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital General de Agudos JM Ramos Mejia</ethicname>
      <ethicaddress>Buenos Aires </ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Italiano de Buenos Aires</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>FUNCEI</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital FJ Muniz</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital de Clinicas Jose de San Martin,</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital General de Agudos Juan A. Fernandez</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Interzonal General de Agudos Oscar Alende</ethicname>
      <ethicaddress>Mar del Plata</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Prof. Alejandro Posadas</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>CAICI</ethicname>
      <ethicaddress>Rosario</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Interzonal de Agudos San Juan de Dios,</ethicname>
      <ethicaddress>la Plata</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital General de Agudos 'Teodoro Alvarez'</ethicname>
      <ethicaddress>Buenos Aires</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Rawson</ethicname>
      <ethicaddress>Cordoba</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Central</ethicname>
      <ethicaddress>Mendoza</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Argentina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Kaplan Medical Center</ethicname>
      <ethicaddress>Rehovot</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sarah Pett M.D</name>
      <address>The National Centre in HIV Epidemiology and Clinical Research
Level 2
376 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 93850900</phone>
      <fax>+61 2 93850910</fax>
      <email>spett@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sarah Pett M.D</name>
      <address>The National Centre in HIV Epidemiology and Clinical Research
Level 2
376 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 93850900</phone>
      <fax>+61 2 93850910</fax>
      <email>spett@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>